The core mechanism of action of ivonescimab involves blockade of key inhibitory signaling pathways, primarily the PD-1/PD-L1 axis, and this blockade aims to reinvigorate exhausted T cells and restore their anti-tumor functionality. Here, CD274 is linked to neoplasm.